Nxera Pharma (formerly Sosei Heptares) has signed an exclusive supply & distribution agreement with Handok for commercializing Pivlaz (clazosentan sodium) 150mg across South Korea
Under the collaboration, Nxera will supply Pivlaz to Handok at an agreed cost while Handok will exclusively handle its promotion, marketing, sales & distribution. Nxera is entitled to receive a one-off upfront upon signing along with commercial milestones & a share of sales generated from product supply
Pivlaz is indicated for preventing cerebral vasospasm, vasospasm-related cerebral infarction & cerebral ischemic symptoms post aneurysmal subarachnoid hemorrhage (aSAH) & will be launched across South Korea in 2025
Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim
Related News:- Boehringer Ingelheim and Sosei Heptares Collaborate for the Development of Therapies to Address Schizophrenia Symptoms
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
